Join Longevity

This Week Was Filled With Threats to Longevity

The Fight for Science: How a Policy Change Threatened Longevity Research—And What Happened Next

A Major Longevity Milestone: FDA Recognizes LOY-002 for Extending Dog Lifespan

Loyal just secured FDA preliminary efficacy acceptance (RXE) for LOY-002, a longevity drug for senior dogs. This brings the first-ever longevity-focused drug closer to market.

ONS Projections: A Surge in Centenarians by Mid-Century

Junevity Raises $10M to Develop a New Obesity Drug That Preserves Muscle Mass

Junevity, fresh from a $10M seed round, is developing an obesity drug that not only reduces weight but also preserves muscle mass and enhances metabolic health.

New Alzheimer’s Trial Targets Disease Decades Before Symptoms Appear

A groundbreaking clinical trial is testing whether an investigational drug by Eli Lilly can prevent Alzheimer’s by removing or blocking amyloid plaques decades before symptoms arise. The study focuses on young adults at high genetic risk, aiming to stop the disease before cognitive decline begins.

Retro Biosciences, OpenAI & Expansion plan

Space-H: Bridging Longevity and Space Exploration

A Breakthrough for Gene Therapies – Extending Their Reach and Impact

Bryan Johnson’s Don’t Die: A Polarizing Dive into the Future of Longevity

Top 5 Longevity Conferences of 2024 and what’s ahead for 2025

ARPA-H’s PROSPR Initiative: A Paradigm Shift in Healthy Aging Research

Digital Innovation Meets Cardiovascular Care: Longenesis Partners with Novartis

Longenesis join forces with Novartis and Daugavpils Regional Hospital to combat cardiovascular diseases through a dynamic digital registry leveraging data-driven insights to improve patient outcomes across the region, enabling more effective and timely treatments.